Introducing XIENCE Skypoint™ Stent 4.5 mm and 5.0 mm Sizes, to Treat Large Vessels
XIENCE Skypoint™ Stent delivers the broadest expansion range in the latest generation XIENCE™ Stent, the DES that consistently delivers successful outcomes—not only in the cath lab, but far beyond. Now available with 4.5 mm and 5.0 mm sizes.2
Treat a Wide Range of Large Vessel Lesions With XIENCE Skypoint™ Stents4
XIENCE Skypoint™ Stent offers a range of stent lengths from 12 mm to 33 mm to help treat a wide range of patients.4
12 mm
to
33 mm
| Stent Diameter | Stent Length | ||||||
| 12 mm | 15 mm | 18 mm | 23 mm | 28 mm | 33 mm | Maximum Expansion | |
| 4.5 mm | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 5.75 mm |
| 5.0 mm | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 5.75 mm |
XIENCE Skypoint™ Stent Shows Accurate Stent Placement With Precise Stent and Marker Placement5
Accurate mid-marker placement enables precise scaffolding and reduces the likelihood of geographic miss to support optimal patient outcomes.5,6
XIENCE Skypoint™ Stent has Significantly Better Longitudinal Strength Than Other DES in Large Vessels7
Longitudinal strength supports better scaffolding in large coronary vessels. Less stent deformation delivers better patient outcomes.8
XIENCE Skypoint™ Stent Shows Significantly Less Stent Deformation Than
Synergy‡ and Resolute Onyx‡ – 5.0 mm Stents
*Denotes significantly different when compared with XIENCE Skypoint™ Stent.
XIENCE™ Stent Shows Improvements in Measures of Quality of Life (QoL) in Patients With Left Main Lesions at 3 Years9
PCI With XIENCE™ Stent in patients with left main lesions showed sustained improvements in QoL out to 3 years9
SAQ - Quality of Life*
*Quality of life is a subscale of the Seattle Angina Questionnaire (SAQ). Scores for each subscale range from 0 to 100 with higher scores representing better health status. Comparison is made vs baseline.
** Denotes statistically significant difference from baseline.
.jpg)
Frequency of Angina-Free Incidences as Measured by SAQ – AF*
* Frequency of Angina is a subscale of the Seattle Angina Questionnaire (SAQ). Comparison is made vs baseline.
** Denotes statistically significant difference from baseline.
XIENCE™ Stent shows significantly lower definite stent thrombosis rates than Synergy‡ in patients with left main lesions at 2 years10
Definite Stent Thrombosis
.jpg)
References
- XIENCE Skypoint™ Stent Instructions For Use (IFU). Refer to IFU for additional information.
- XIENCE Skypoint™ Stent – Instructions for Use (IFU). Refer to IFU for additional information. Zanchin, C. et al. J Am Coll Cardiol Intv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Kufner S, et al. Circulation. 2019:139(3):325-333.
- Data on file at Abbott.
- XIENCE Skypoint™ Stent – Instructions for Use (IFU). Refer to IFU for additional information.
- Data on file at Abbott. XIENCE Skypoint™ Stent vs. Synergy‡ and Resolute Onyx‡ – 5.0 x 18 or 20 mm stents tested.
- Costa M, et al. Am J Cardiol. 2008;101:1704-1711; Sudhir, K., et al. ISRN Cardiology. 2013:1-8.
- Data on file at Abbott. XIENCE Skypoint™ Stent – 5.0 x 33 mm, n=5. Synergy‡ 5.0 x 32 mm, n=2. Resolute Onyx‡ – 5.0 x 33 mm , n=5. *Denotes significantly different when compared with XIENCE Skypoint™ Stent. Longitudinal stent compression test was done using 50 gf load.
- Shand J, et al. Interv Cardiol. 2012;4:325-335.
- Baron S, et al. J Am Coll Cardiol. 2017;70:3113-3122.
- Van Geuns R, et al. IDEAL-LM. TCT 2019
MAT-2413707 V1.0
